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ABSTRAK
Program saringan talasemia telah diwujudkan di Malaysia semenjak tahun 2004. 
Program ini bertujuan untuk mengurangkan beban akibat penyakit ini dengan 
mengenal-pasti pembawa talasemia. Walaubagaimanapun, sambutan terhadap 
aktiviti saringan ini didapati kurang memuaskan kerana kurangnya kesedaran orang 
ramai akan kepentingan saringan talasemia. Kaedah alternatif adalah menyaring 
penderma darah. Matlamat kajian ini adalah untuk mengetahui prevalens 
pembawa talasemia di kalangan penderma darah yang sihat. Tujuh ratus tiga 
puluh lapan penderma darah yang sihat telah disaring di Hospital Tengku Ampuan 
Rahimah, Klang menggunakan kaedah cation-exchange high performance liquid 
chromatography (HPLC) dari Julai hingga September 2010. Semua kes varian 
hemoglobin seterusnya diproses menggunakan gel electrophoresis pada pH alkali.
Hasil kajian menunjukkan penderma darah terdiri daripada bangsa Melayu 413 
(56%), India 162 (22%), Cina 148 (20%) and lain-lain 15 (2%). Terdapat 19 (2.6%) 
trait hemoglobin E, enam (0.8%) hemoglobin E/talasemia-αα dan lima (0.7%) 
trait talasemia-β. Hemoglobin Constant Spring dan hemoglobin A2 prime dilihat 
dalam dua (0.3%) kes; dan Hemoglobin Lepore serta varian rantaian alpha dalam 
satu (0.2%) kes. Walaubagaimanapun talasemia-αα dan talasemia-β hemoglobin 
A2 normal tidak boleh diabaikan dalam 190 (26%) kes dan memerlukan analisa 
DNA untuk pengenalpastian jenis talasemia tersebut. Saringan talasemia ke atas 
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penderma darah adalah lebih mudah dan berkesan. Oleh yang demikian, saringan 
populasi yang meluas termasuk penderma darah boleh memberi faedah kepada 
program saringan talasemia yang sedia ada di Malaysia. 
Kata kunci: saringan talasemia, penderma darah, varian hemoglobin, Malaysia
ABSTRACT 
Thalassaemia screening programme has been conducted in Malaysia since 2004. 
The aim of the programme was to reduce the burden of the disease by identifying 
thalassaemia carriers. However, the response towards the screening activities was 
unsatisfactory as there was lack of public awareness against the importance of 
thalassaemia screening. An alternative approach is to screen blood donors. The 
purpose of this study was to observe the prevalence of thalassaemia carriers among 
healthy blood donors. Seven hundred and thirty eight healthy blood donors were 
screened in Hospital Tengku Ampuan Rahimah, Klang from July to September 2010 
using cation-exchange high performance liquid chromatography (HPLC). Cases 
with haemoglobin variants were further analyzed by gel electrophoresis at alkaline 
pH. Result shows that the blood donors consisted of 413 Malays (56%), 162 Indians 
(22%), 148 Chinese (20%) and 15 others (2%). There were  19 (2.6%) individuals 
with haemoglobin E trait, six (0.8%) with co-inheritance of haemoglobin E and αα-
thalassaemia and five (0.7%) with β-thalassaemia trait. Haemoglobin Constant Spring 
and haemoglobin A2 prime were observed in two (0.3%); and Haemoglobin Lepore 
and alpha chain variant in one (0.2%). αα-thalassaemia and normal haemoglobin 
A2 β-thalassaemia could not be excluded in 190 cases (26%), as they required 
deoxyribonucleic acid (DNA) studies for identification. Thalassaemia screening in 
blood donors is more feasible and effective. Therefore, a wider scale population 
screening including blood donors could benefit the existing thalassaemia screening 
programme in Malaysia.
Keywords: thalassaemia screening, blood donors, haemoglobin variants, Malaysia
These programmes mainly focussed 
on couples of childbearing age either 
before or during pregnancy. It was also 
offered as a premarital screening in 
order to help carriers to make informed 
decision on the choice of marital partner, 
since marriage between carriers is not 
encouraged. Since 2004, Malaysia has 
carried out screening activities through 
two different approaches on volunteer 
participants. In cascade screening, the 
INTRODUCTION
Thalassaemia and haemoglobinopathies 
not only result in serious health problem, 
but also creates a heavy economic 
burden to the country (George 2001). 
Therefore, many countries including 
Malaysia have established thalassaemia 
screening programmes (HKCOG 2003; 
Samavat & Modell et al. 2004; MOH 
2009) in order to identify carriers. 
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close relatives of the patients would be 
tested, while in target screening, it may 
involve expecting mothers, adolescents 
in schools and colleges, and also those 
who are attending the government 
health care centres (MOH 2009). 
However, even though the screening 
for thalassaemia is free of charge, the 
response rate is poor in our nation 
due to lack of awareness, especially in 
lower educated individuals (Anjanna et 
al. 2011; Wong et al. 2011).
 While campaigns are consistently 
carried out to improve public 
awareness and to encourage target 
groups to participate in voluntary 
thalassaemia screening, an alternative 
and a feasible approach would be to 
screen blood donors. In our practice, 
the blood donors are clinically assessed 
for medical illnesses through standard 
questionnaires and simple physical 
examinations. The pre-donation 
haemoglobin level is also measured 
with minimal cut-off of 12.5 g/dL as the 
acceptance criteria. Prospective donors 
who are healthy with haemoglobin 
levels within the normal range are 
permitted for blood donation. In order 
to prevent the adverse effect of blood 
donation to the donors as well as the 
recipients, the donated blood is always 
screened for transfusion-transmissable 
infections. Regarding these sequences 
of donor selection and screening tests, 
we might miss donors with thalassaemia 
trait because carriers of thalassaemia 
are asymptomatic in general and their 
haemoglobin values are sometimes 
above the minimal requirement (Bryant 
et al. 2009). In the present study, 
thalassaemia screening was carried 
out on post-donated blood to find out 
the prevalence of thalassaemia carrier 
among healthy blood donors. 
MATERIALS AND METHODS
A cross-sectional study was conducted 
on routine diagnostic samples sent 
for thalassaemia sceening in Institute 
for Medical Research. A total of 738 
samples from Malaysian blood donors 
were received from Tengku Ampuan 
Rahimah Hospital from July until 
September 2010. The donors were 
explained about the purpose of the 
study and consent were obtained 
from each of them prior to the blood 
taking. They were selected according 
to the standard criteria prepared by 
the hospital including age between 
18 and 65 years old, minimum weight 
of 45 kg and minimum of five hours 
sleep. Healthy donors with acceptable 
haemoglobin level were allowed to 
donate when the time interval from the 
last donation was at least eight weeks. 
The acceptable haemoglobin level was 
presumed ranging from 12.5 to 18.0 
g/dl if the donors passed the copper 
sulphate gravimetric test. 
 Five ml of venous blood 
specimen were collected in 
ethylenediaminetetraacetic acid (EDTA) 
tube during the blood donation process. 
Full blood count was performed by 
an automated haematology analyzer, 
Sysmex XE-2100D and Sysmex XE-
2100 Alpha  (Sysmex, Japan) in the 
hospital on the day of collection, while 
further analyses were conducted in 
Institute for Medical Research on the 
next day (within 48 hours). We used 
Bio–Rad VARIANT II Haemoglobin 
Testing System (Hercules, USA), a 
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fully automated cation-exchange high 
performance liquid chromatography 
(HPLC) for haemoglobin analysis. 
Agarose gel electrophoresis using Sebia 
Hydrasis (Sebia, France) at alkaline pH 
(8.6) was only done on samples with 
detected haemoglobin (Hb) variants on 
HPLC.
 The cut-off level for haemoglobin 
A2 of more than 4.0% was used for 
presumptive diagnosis of classical 
β-thalassaemia trait (George et al. 
2001). But if it was more than 10%, a 
diagnosis of haemoglobin Lepore was 
considered, while the level more than 
25% was interpreted as suggestive 
of haemoglobin E trait (Barbara 
2006; Ryan et al. 2010). However, 
when the level was between 16 to 
25%, haemoglobin E with alpha 
thalassaemia, co-inheritance was 
suggested (Barbara 2006; Ryan et al. 
2010). The presence of other abnormal 
peaks in HPLC chromatogram was 
correlated with the demographic data 
and gel electrophoresis result.
 All statistical analyses were 
conducted using the Statistical Package 
for Social Sciences for Windows SPSS 
17.5 (SPSS inc., Chicago, IL, USA). The 
results were expressed as mean + 2 
standard deviation (SD).
RESULTS
Among 738 blood donors, 606 (82%) 
were males and  132 (18%) were 
females. The mean age was 33 years and 
SD was 10. The youngest donors were 
aged 17 years while the oldest were 
61 years. Four hundred and thirteen 
(56%) were Malays, 162 (22%) were 
Indians, 148 (20%) were Chinese while 
15 (2%) were others. The other races 
consisted of Iban 2, (0.3%), Kadazan 1 
(0.2%), Kayan 1 (0.2%), Bugis 1 (0.2%) 
and Malaysian-Indonesian 1 (0.2%); 
while 9  (1.2%) donors did not specify 
their ethnicity. Seventy four (10%) of 
the blood donors were confirmed to 
have haemoglobin levels below 12.5 
g/dL (8.7-12.4 g/dL), where four (5.4%) 
had haemoglobinopathies. Mean 
corpuscular haemoglobin (MCH) level 
lower than 27 pg was observed in 225 
(30.5%) donors, of whom 35 (15.6%) 
displayed abnormal haemoglobin 
fractions on HPLC. Interestingly, 
haemoglobinopathy (haemoglobin 
A2 prime) was found in one (0.1%) 
donor whose MCH value was within 
the normal range (28.2 pg) but the 
mean corpuscular volume (MCV)
value was 79.7 fL. The other types of 
haemoglobinopathies detected with 
their haematological parameters shown 
in Table 1. All the abnormal cases were 
Malays except for the β-thalassaemia 
trait cases, three (60%) were Indians 
and two (40%) were Malays. 
 αα-thalassaemia and normal 
haemoglobin A2 β-thalassaemia carriers 
were not be able to be excluded in 190 
(25.7%) cases based on our screening 
tests. The diagnosis would only be 
confirmed by molecular analysis. Male 
donors were predominant in this group 
140, (73.7%). Malays accounted for 104 
(54.7%), Indians 65 (34.2%) Chinese 20 
(10.5%) and others one (0.5%). Fourty 
six (24.2%) donors had haemoglobin 
less than 12.5 g/dL (8.7-12.4 g/dL) and 
the median haemoglobin level was 11.6 
g/dL. The haematological parameters 
for these 190 undiagnosed cases shown 
in Table 2.
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DISCUSSION
The severe types of thalassaemia that 
pose major public health problem 
in Malaysia are homozygous αα0-
thalassaemia (haemoglobin Bart’s 
hydrops foetalis) and β-thalassaemia 
major (Ainoon & Cheong 1994). 
Homozygous αα0-thalassaemia is 
associated with perinatal mortality and 
potentially causing fatal pregnancy 
complications in mothers. Children 
with β-thalassaemia major are always 
manifested with severe anaemia after 
one year of age requiring lifelong blood 
transfusion. Since, they are transfusion 
dependent, iron chelators are 
important to overcome iron overload 
Table 2: Haematological 
parameters of undiagnosed cases
Blood Indices Mean ± SD Value Range 
Hb (g/dl) 13.6 ±1.5 8.7 - 16.9 
Hct 43.5 ± 3.8 31.6 - 51.3
RBC (1012/l) 5.4 ± 0.5 4.0 - 6.8
MCV (fl) 80.1 ± 4.7 64.5 – 88.4
MCH (pg) 25.0 ± 1.8 17.7 – 26.9
MCHC (g/dl) 31.2 ± 1.3 26.6 – 42.0
RDW (fl) 41.7 ± 4.0 12.0 – 51.0
Hb A2 (%) 2.6 ± 0.3 1.5 – 3.7
Hb F (%) 0.4 ± 0.5 0.1 – 5.0
Table 1: Haematological parameters of variant haemoglobin and β-thalassaemia trait
Blood 
Indices
Hb E trait 
(n=19) 
2.6%
Hb E/α 
(n=6) 
0.8%
β-thalassaemia 
trait 
(n=5) 0.7%
Hb 
Constant 
Spring 
(n=2) 
0.3%
Hb A2 
prime 
(n=2) 
0.3%
Hb 
Lepore 
(n=1) 
0.1%
Alpha 
chain 
variant 
(n=1) 
0.1%
Hb (g/dL) 13.9 ± 1.3 (11.3-16.4)
14.1 ± 0.9 
(13.0-15.1)
13.4 ± 1.2 
(12.1-14.7)
13.7 ± 1.1 
(12.9-14.4)
14.8 ± 0.1 
(14.7-14.8) 14.4 15.5
Hct (%) 42.9 ± 3.4 (35.8-48.6)
44.6 ± 2.2 
(40.8-47.1)
43.1 ± 3.5 
(38.7-47.2)
44.0 ± 2.0 
(42.6-45.4)
43.9 ±3.3 
(41.6-46.2) 46.7 48.3
RBC (1012/L) 5.7 ± 0.5 (4.8-6.8)
5.9 ± 0.4 
(5.2-6.5)
6.6 ± 1.0
 (5.0-7.9)
5.7 ± 0.3 
(5.0-5.9)
5.6 ± 0.5 
(5.2-6.0) 6.93 5.82
MCV (fL)
75.1 ± 2.4 
(71.3-79.3)
75.9 ± 4.8 
(67.2-80.5)
66.3 ± 12.1 
(58.4-87.3)
77.2 ± 7.4 
(72.0-82.4)
78.6 ± 1.6 
(77.4-79.7) 67.4 83.0
MCH (pg) 24.3 ± 1.2 (22.4-26.8)
24.1 ± 2.1 
(20.1-25.6)
20.7 ± 3.6 
(18.3-26.7)
24.0 ± 3.0 
(21.8-26.1)
26.5 ± 2.4 
(24.8-28.2) 20.8 26.6
MCHC (g/dL) 32.4 ± 1.1 (30.6-35.1)
31.7 ± 0.9 
(30.0-32.3)
31.2 ± 0.5 
(30.6-32.0)
31.0 ± 1.0 
(30.3-31.7)
33.7 ± 2.3 
(32.0-35.3) 30.8 32.1
RDW (%) 38.4 ± 1.7 (34.0-42.0)
40.7 ± 3.5 
(37.0-47.0)
37.3 ± 5.0 
(34.0-46.0)
40.7 ± 0.7 
(40.2-41.2)
43.0 ± 0.4 
(42.7-43.2) 39.3 39.9
Hb A2 (%)
26.4 ± 0.8 
(25.1-28.2)
23.5  ± 1.3 
(21.0-24.4)
5.2 ± 0.9 
(4.2-6.4)
2.6 ± 0.1 
((2.5-2.7)
1.55 ± 0.1 
(1.5-1.6) 11.7 2.1
Hb F (%) 0.7 ± 0.3 (0.3-1.5)
0.7 ± 0.3 
(0.3-1.2)
0.6 ± 0.4
 (0.2-1.1)
1.2 ± 1.0 
(0.5-1.9)
0.8 ± 0.6 
(0.3-1.2) 3.1 0.1
Data reported as mean±SD RBC: red blood cell 
( ): minimum and maximum level MCV: mean corpuscular volume
Hb: haemoglobin MCH: mean corpuscular haemoglobin
Hct: haematocrit RDW: Red cell distribution width
MCHC: mean corpuscular hemoglobin concentration
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complications. However, prior to year 
2005, less than 20% of them receive 
adequate treatment (George 2001). 
This not only affects the clinical 
health status, but also gives a great 
impact on our socio-economy. Hence, 
establishment of screening programme 
for identification of thalassaemia carrier 
is extremely crucial. The most effective 
approach is the implementation of 
screening programme among school 
students, premarital couples, family 
members of thalassaemia patients and 
pregnant women during antenatal 
booking (Bianco et al. 1984; Samavat & 
Modell 2004; AlHamdan et al. 2007). 
But a feasible option is to also test blood 
donors as the blood sample is readily 
available at time of blood donation. In 
general, this approach can enhance our 
national screening programme since the 
response rate is poor in our community 
(Anjanna et al. 2011; Wong et al. 2011). 
Lack of knowledge and unwillingness 
for screening were the main reason for 
the poor response (Anjanna et al. 2011; 
Wong et al. 2011). 
 Few studies reported the success of 
thalassaemia screening programme at 
school but few have raised arguments 
against this practice (Troitskaia et al. 
1999; AlArrayed et al. 2003; Li et al. 2009). 
School students are considered legally 
minors. Their assents in participating 
carrier testing may be influenced by 
friends, teachers and guardians (Ross 
2006). The possibilities of confusion 
between carrier state and being 
affected by the disease might occur in 
the absence of proper counselling and 
this can lead to adverse psychological 
reaction in those with positive results 
(Axworthy et al. 1996; Marteau et al. 
1992; Stewart-Brown & Farmer 1997). 
Based on ethical issues, genetic testing 
like thalassaemia screening can only 
be carried out if immediate diagnosis 
is necessary, for instance when an 
adolescent is pregnant or planning for 
pregnancy (ASHG/ACMG 1995). At this 
age, screening would be acceptable. 
The test should be deferred until they 
are able to justify the appropriate 
time to have the screening (Frumkin 
& Zlotogora 2008). Adolescents aged 
18 and above are generally legal 
for consent because (ASHG/ACMG 
1995) they are considered mature and 
capable in making judgment for their 
future. Married blood donors who are 
identified as thalassaemia trait would 
alert their spouses to get a similar test 
in order to ascertain their carrier status. 
If they are at risk of having children 
with thalassaemia major, they would 
then be counselled to undergo prenatal 
diagnostic test, so that they can have 
the option of either continuing or 
terminating the affected pregnancy. 
This, however results in difficult decision 
making caused by misapprehension 
of the disorders, cultural values and 
religious belief (El-Hazmi 2009; Wong 
et al. 2011). Premarital screening 
would be an alternative way since this 
approach might be more effective in 
the Malay community. It may identify 
carrier couples, thus giving them the 
opportunity to circumvent affected 
pregnancies. Studies showed that the 
incidence of infants born with the 
disease reduced tremendously by 
implementation of premarital screening 
(Zlotogora 2009).
 In the present study we found that 
36 (5%) of 738 healthy blood donors 
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were presumptively diagnosed as 
thalassaemia carriers. The frequency 
of haemoglobin E carrier was similar 
with the previous study (George & 
Khuziah 1984), but the distribution 
of β-thalassaemia carrier and 
heterozygous haemoglobin Constant 
Spring were below the reported 
incidence (George 2001; Wee et al. 
2009). αα-thalassaemia and normal 
haemoglobin A2 β-thalassaemia 
could not be excluded in 190 (25.7%) 
blood donors in this study because no 
abnormal pattern was noted in HPLC 
result. Further confirmation by DNA 
analysis on these cases demand for 
futher analysis in the future. 
 Anaemic blood donors are no longer 
an issue, because further workup will 
be initiated to find out the cause of 
anaemia. Nonetheless, for those who 
pass copper sulphate test, they are 
always considered to have normal 
haemoglobin level. Therefore they will 
be permitted for blood donation and 
missed from detection of thalassaemia 
trait. A few studies had found this 
method was less sensitive in detecting 
anaemia compared with other 
portable haemoglobinometry devices 
available in the market (Newman 
1997; Nadarajan & Eow 2002; Boulton 
2008). It is not cost-effective to include 
haemoglobin analysis as routine blood 
test in blood donors in order to screen 
for thalassaemia carrier. Besides, it is 
troublesome to potential blood donors 
and can negatively impact the blood 
donor return. In this study, majority 
(70%) of the blood donors had results 
within normal limits. A local study 
which included anaemic blood donors 
also found that 84% of them had 
normal haemoglobin electrophoresis 
pattern (Rosline et al. 2006). Therefore, 
performing haemogram on initial 
diverted blood from collateral pouch 
after blood donation would be 
more worthwhile. More accurate 
haemoglobin level would be measured 
and more detail blood cell indices 
would be scrutinized. Based on these 
results, certain donors will be selected 
for complete haemoglobin analysis. 
According to British Committee for 
Standards in Haematology (British 
Journal of Haematology 2010), MCH 
value is the recommended parameter 
for thalassaemia screening as it is 
more stable than MCV. We had only 
one case with detected haemoglobin 
variant on HPLC, yet the MCH value 
was normal (more than 27 pg) while 
the MCV value was 79.7 fL. A previous 
study that adopted MCV level of less 
than 80 fL as a criterion for further 
analysis in apheresis blood donors 
had found that 36% of the donors 
had haemoglobinopathy (Bryant et al. 
2009). Such findings showed that both 
MCV and MCH values are essential for 
prediction of thalassaemia trait. 
 It is highly debated whether or not 
thalassaemia and haemoglobinopathy 
screening should be done for regular 
blood donors to avoid transfusion of 
dysfunctional red cells and transfusion 
acquired haemoglobinopathy. Rational 
for screening most often depends 
on the demographic frequency of 
thalassaemia and clinically significant 
haemoglobinopathies in a given 
population and special requirement 
of recipients. In addition to this, post 
transfusion lifespan of erythrocyte is 
also an important factor in transfusion 
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medicine. Erythrokinetic of thalassaemic 
red cells in a normal recipient showed 
25 to 50% of transfused cells were 
destroyed within 10 to 20 days 
rendering the transfusion relatively 
ineffective (Kaplan & Zuelzer 1950). 
Similarly, haemoglobin E, an unstable 
haemoglobin with increased sensitivity 
to oxidants showed a shortened red cell 
survival. In United Kingdom, testing of 
blood cell products for haemoglobin S 
are undertaken when the prospective 
recipients are in paediatric age group 
and neonatal patients (JPAC 2005). 
However, this policy is deferred at the 
Northern Ireland Blood Transfusion 
Services until contemporary ethnicity 
was fully understood (Northern Ireland 
Blood Transfusion Service, 2012). A 
local study may be necessary to assess 
the effect of transfusing thalassaemic 
blood in patients before considering 
such screening test in our blood 
products.
CONCLUSION
Thalassaemia screening among healthy 
blood donors could benefit the existing 
thalassaemia screening programme in 
Malaysia. It is a feasible and effective 
approach in detecting thalassaemia 
carriers in our population. However, 
a more cost-effective screening 
method is suggested since prevalence 
of thalassaemia carrier in healthy 
blood donors are low. Haemogram 
is an appropriate screening test as 
scrutinisation of blood indices may 
allow selection of blood donors for 
further analysis of haemoglobin.
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